Bupropion Hydrochloride Extended-Release Articles
Teva/Impax generic Wellbutrin XL 300mg pulled from US market on non-bioequivalence grounds
4 October 2012
GlaxoSmithKline to refocus some research and seek efficiencies, despite posting huge 4th-qtr 2009 profits rise; applause from Science Minister
5 February 2010
GlaxoSmithKline beats forecasts with 3rd quarter2009 profits leaping 34%, despite generic competition
28 October 2009
GSK sells US Wellbutrin rights for $510M
6 May 2009
Final FDA appro for Watson's generic Wellbutrin
1 December 2008
Actavis opens R&D laboratory in Florida
10 November 2008
Teva's 2nd-qtr 2008 profit up 5% to $539M
18 August 2008
FDA questions switch to Teva's Bupropion
28 April 2008
Stock Commentary - New York week to June 18, 2007
25 June 2007
Watson's generic Welbutrin cleared by FDA
25 June 2007
GSK posts solid results for 1st-qtr 2007 with a 14% EPS rise despite US generic pressure
30 April 2007
Watson gets $35M in GSK patent settlement
19 February 2007
FDA citizen petitions 'abused' by drug firms
17 July 2006
Biovail's 2005 revenue reaches $936M
3 April 2006
Anchem submits US ANDA for Wellbutrin XL
22 November 2004
Biovail revises full-year outlook on robust sales
20 September 2004
GSK's 2nd-qtr 2004 EPS drops 12%
2 August 2004
GSK's 1st-qtr profit continues decline
10 May 2004
Green light for 150mg Wellbutrin generics
29 March 2004
Biovail revises 2004 guidance
15 March 2004
GSK exercises option for Biovail's Wellbutrin XL
15 December 2003
Biovail stock recovers ground as investors return to calm
20 October 2003
GSK's Wellbutrin XL on track for approval
7 July 2003
GSK plans six product filings in 2002
18 February 2002
GW hits Impax with bupropion lawsuits
10 October 2000
Showing 1-38 of 38 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
